OncoMatch/Clinical Trials/NCT06679829
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Is NCT06679829 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Siltuximab and Melphalan for multiple myeloma.
Treatment: Siltuximab · Melphalan — The purpose of this study is to see if siltuximab plus population pharmacokinetic (PK)-dosed melphalan works as well as the usual approach (body surface area \[BSA\]-dosed melphalan) in people with multiple myeloma (MM) who are receiving an autologous stem cell transplant (ASCT) as part of their standard treatment. The researchers will also see if siltuximab in combination with population PK-dosed melphalan works to decrease symptoms after an ASCT, and will study the safety of siltuximab. For the run-in, 15 patients will receive siltuximab, 11 mg/kg, seven days before and 14 days after autologous hematopoietic stem cell infusion (+/-2 day).
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Must have received: autologous stem cell transplant — planned
undergoing autologous HCT with plan off study for melphalan 140 or 200 mg/m2 undergoing HCT within 12 months of diagnosis
Cannot have received: IL-6 or IL-6 receptor targeting agent
Prior exposure to agents targeting IL-6 or the IL-6 receptor
Lab requirements
Blood counts
Platelet count ≥ 20 x 10^9/L
Kidney function
Calculated creatinine clearance > 40 mL/min
Liver function
ALT and AST ≤ 2.5 x ULN; Total bilirubin ≤ 2.5 x ULN; except if the elevation is due to Gilbert's syndrome
Cardiac function
LVEF >45% by MUGA or rest ECHO; QTc >460ms by Fridericia excluded (if bundle branch block or intraventricular conduction delay, exclusion for >500ms by Friderica); ischemic heart disease requiring intervention in prior 3 months or uncontrolled heart failure or arrhythmia excluded
Diffusion capacity >45% (adjusted for hemoglobin) as predicted by pulmonary function testing. LVEF >45% by MUGA or rest ECHO. Platelet count ≥ 20 x 10^9/L. ALT and AST ≤ 2.5 x ULN; Total bilirubin ≤ 2.5 x ULN; except if the elevation is due to Gilbert's syndrome. Calculated creatinine clearance > 40 mL/min. QTc >460ms by Fridericia excluded (if bundle branch block or intraventricular conduction delay, exclusion for >500ms by Friderica).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify